Malignant lymphoma of the testis: a study of 12 cases

Lantz, Andrea G.; Power, Nicholas; Hutton, Brian; Gupta, Rekha

doi:10.5489/cuaj.1153

Cited by 40 publications

(54 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17%, respectively, which was comparable with the results of pre vious reports in which the median OS period of limited staged disease ranged from 5.3 years to 6.3 years and the 5 year OS rate ranged from 58% to 85%. 7,8,12,14 The most favorable treatment result was reported by Vitolo et al, 12 in which all patients underwent a treatment protocol comprising orchidectomy, R CHOP, CNS pro phylaxis, and contralateral testis irradiation. In comparison with the results of Vitolo et al, 12 our patients received a different treat ment protocol, and many patients did not receive complete R CHOP chemotherapy regimens, prophylactic radiotherapy, or intrathecal chemotherapy.…”

Section: Discussionmentioning

confidence: 88%

“…The clinical characteristics of the patients in this study were similar to those previously reported. 1,2,4,5,7,8,11,13,14 In addition to old age, the majority of patients presented with uni lateral stages IeII lymphoma and DLBCL. These observations sug gest that the characteristics of PTL appear to be similar worldwide.…”

Section: Discussionmentioning

confidence: 99%

“…Approximately 25e41% men with PTL present with B symptoms (fever, night sweats, and weight loss) 6 and approximately 26e37% cases have elevated LDH levels. 6,7,11,14 In this study, the patients were divided using the Ann Arbor staging system as follows: limited (stages IeII) and advanced (stages IIIeIV) stages. The median survival time was 76 months versus 12 months and the 5 year OS rate was 61% versus Table 2 Treatments and outcomes of 30 primary testicular lymphoma patients.…”

Section: Discussionmentioning

confidence: 99%

“…5,10 In addition, PTL shows a predilection for spreading to extranodal sites, primarily to the central nervous system (CNS) and contralateral testis, and is associated with a high risk of relapse, even years after a complete treatment response. 7,8 Consequently, recent reports recommend using a prophylactic approach that utilizes both sys temic and intrathecal chemotherapy, as well as scrotal and lymphatic radiotherapy, in addition to locoregional treatment. 5,9,11 In an international Phase II trial, the approach adopted by Vitolo et al, 12 which incorporated a combined treatment of conventional chemotherapy, CNS prophylaxis, and contralateral testis radio therapy, was associated with good outcomes in patients with PTL.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A retrospective study of clinical characteristics and prognostic factors of primary testicular lymphoma

et al. 2013

View full text Add to dashboard Cite

a b s t r a c tObjective: To assess the clinical characteristics, prognostic factors, and treatment outcomes of primary testicular lymphoma (PTL). Materials and Methods: We reviewed the medical records of PTL patients diagnosed between January 2000 and May 2012 at four hospitals in Taiwan. The following data were collected and analyzed: patient age at diagnosis, B symptoms (fever, night sweats, and/or weight loss), tumor localization (diffuse or testis alone), tumor site (left, right, or bilateral), stage of disease, histological pattern, International Prognostic Index, treatment method and outcome, relapse, and survival time. Kaplan Meier curves were constructed to assess the effects of various factors on patient survival. Results: Thirty patients with PTL were included in this study. The median age at diagnosis was 62.5 years (range: 19 89 years) and median overall survival (OS) was 44 months. The majority of the patients had unilateral lymphoma, stage I/II disease, and diffuse large B cell lymphoma. An absence of B symptoms, limited disease stage, lymphoma localized to testis only, and orchidectomy were considered to be significantly favorable prognostic factors of OS (p < 0.05). The PTL treatment regimen varied among patients and included orchidectomy, chemotherapy, and/or radiotherapy. Interestingly, although 50% patients achieved complete remission (CR) post treatment, relapse was observed in 42% patients during the follow up period. Nonetheless, patients who initially underwent orchidectomy appeared to have a significantly better survival rate, whereas chemotherapy proved more advantageous for those with the diffuse type PTL. Conclusion: PTL is characterized by unique clinical features and prognostic factors. Despite differing treatment regimens, 50% of patients achieved CR. Patients with testicular localization who underwent orchidectomy may achieve better outcomes, whereas chemotherapy proved to be beneficial in those with diffuse type PTL.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A retrospective study of clinical characteristics and prognostic factors of primary testicular lymphoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…A TNHL-lel diagnosztizált betegek leggyakoribb panasza az első orvos-beteg találkozás alkalmával az egyik vagy mindkét here duzzanata, másodsorban ismeretlen okú testtömegcsökkenést, továbbá lázat és éjszakai izzadást említenek [4]. A daganat irreguláris, hipodenz inhomogenitást mutat az ultrahangképen, amely általában már a kezdetekkor felveti a malignitás gyanúját.…”

unclassified

Diagnosis and treatment of primary testicular non-Hodgkin lymphoma

et al. 2014

View full text Add to dashboard Cite

A primer testicularis non-Hodgkin-lymphoma igen ritka, főleg időskorban előforduló betegség, amely 1%-át adja az összes non-Hodgkin-és 2%-át az extranodalis lymphomáknak, a heretumoroknak pedig összesen 5%-ában fordul elő. Az entitást először 1866-ban írták le, ám a mai napig igen ritka és multidiszciplináris terápiát igénylő kórállapot, amely az időben megkezdett és adekvát kezelés nélkül letális lehet. A szerzők a testicularis non-Hodgkin-lymphoma felismerését, tulajdonságait és a társszakmák bevonásával történő kezelési lehetőségeit kívánják bemutatni egy általuk kezelt 68 éves beteg esetén keresztül, aki a primer testicularis non-Hodgkin-lymphoma felismerését követően orchidectomiában, majd kemo-és radioterápiában részesült. A kezelést követő kontroll PET-CT és liquorvizsgálat nem talált daganatot vagy patológiás sejtalakokat, a kezeléssel a lymphoma teljes remisszióját érték el. Orv. Hetil., 2014, 155(2), 69-71. Kulcsszavak: primer, testicularis, non-Hodgkin-lymphoma Diagnosis and treatment of primary testicular non-Hodgkin lymphomaThe primary testicular non-Hodgkin lymphoma, which has been fi rst described in 1866, is a very uncommon type of urological neoplasia occuring mostly in the elderly ages. It only gives 5% of the testicular tumors, 2% of extranodal lymphomas, and barely 1% of all non-Hodgkin diseases. Patients with testicular non-Hodgkin lymphomas need prompt multidisciplinary aid because without treatment the outcome can be unfavorable. The authors discuss the attributes, diagnostic modalities and treatment options of the primary testicular non-Hodgkin lymphoma and present a case of a 68-year-old patient who underwent orchiectomy, chemo-and radiotherapy after having been diagnosed with the tumor. The follow-up PET-CT and cerebrospinal fl uid analysis found no further sign of the disease, and complete remission has been achieved. Keywords: primary, testicular, non-Hodgkin lymphomaRomics, M., Demeter, J., Romics, I., Nyirády, P. (2014). [Diagnosis and treatment of primary testicular non-Hodgkin lymphoma]. Orv. Hetil., 155(2), 69-71.(Beérkezett: 2013. november 4.; elfogadva: november 21.) Rövidítések AFP = alfa-fötoprotein; β-HCG = humán choriogonin-β; CHOP = cyclophosphamid, doxorubicin, vincristin és prednison; LDH = laktátdehidrogenáz; TNHL = testicularis nonHodgkin-lymphoma A primer testicularis non-Hodgkin-lymphomát (TNHL), amely szemben más heredaganatokkal, főként idősebb korban fordul elő, először 1866-ban Malassew és Curling írta le. A TNHL a leggyakrabban előforduló primer és szekunder heretumor 50 éves kor felett, ám a heredaganatoknak csak 5%-át teszi ki. A TNHL a non-Hodgkin-lymphomák 1%-át, míg az extranodalis lymphomák csupán 2%-át alkotja, de felismerése rendkívül fontos, ugyanis kezelés nélkül a beteg halálához vezet [1,2]. Szintén fontos megjegyezni, hogy a heredaganatok közt

show abstract